- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Spring 2013
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
| Novartis Pharma. Corp. v. Alvogen Pine Brook, Inc., 13-0052 (D. Del.) | Jan. 4, 2013 | Hon. Richard G. Andrews | Exelon® Patch (rivastigmine transdermal system or extended-release film) | 6,316,023; 6,335,031 |
| AstraZeneca AB v. Dr. Reddy’s Labs., Inc., 13-0091 (D.N.J.) | Jan. 4, 2013 | Hon. Joel A. Pisano | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 6,926,907; 5,714,504; 7,745,466; 7,411,070; 6,369,085 |
| Allergan, Inc. v. Apotex Inc., 13-0016 (M.D.N.C.) | Jan. 8, 2013 | Hon. Catherine C. Eagles | Latisse® (bimatoprost topical solution, 0.03%) | 8,263,054 |
| Cadence Pharma., Inc. v. Fresenius Kabi USA, LLC, 13-0139 (S.D. Ca.) | Jan. 17, 2013 | Hon. Dana M. Sabraw | Ofirmev® (acetaminophen for injection) | 6,028,222; 6,992,218 |
| Horizon Pharma, Inc. v. Par Pharma. Cos., Inc., 13-0102 (D. Del.) | Jan. 17, 2013 | Hon. Leonard P. Stark | Duexis® (famotidine / ibuprofen tablets) | 8,309,127; 8,318,202 |
| Cadence Pharma., Inc. v. Fresenius Kabi USA, LLC, 13-0453 (N.D. Ill.) | Jan. 18, 2013 | Hon. Gary Feinerman | Ofirmev® (acetaminophen for injection) | 6,028,222; 6,992,218 |
| Jazz Pharma., Inc. v. Amneal Pharma., LLC, 13-0391 (N.J.D) | Jan. 18, 2013 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 6,472,431; 6,780,889; 7,262,219; 7,851,506; 7,895,059; 8,263,650; 8,324,275 |
| Endo Pharma. Inc. v. Impax Labs., Inc., 13-0435 (S.D.N.Y.) | Jan. 18, 2013 | Hon. Thomas P. Griesa | Opana® ER (oxymorphone hydrochloride extended-release tablets) | 7,851,482; 8,114,383; 8,192,722; 8,309,122; 8,309,060; 8,329,216 |
| Endo Pharma. Inc. v. Actavis, Inc., 13-0436 (S.D.N.Y.) | Jan. 18, 2013 | Hon. Thomas P. Griesa | Opana® ER (oxymorphone hydrochloride extended-release tablets) | 7,851,482; 8,114,383; 8,192,722; 8,309,122; 8,309,060; 8,329,216 |
| Hoffman-La Roche Inc. v. Aurobindo Pharma Ltd., 13-0124 (D. Del.) | Jan. 22, 2013 | Hon Leonard P. Stark | Boniva® Once-Monthly (ibandronate sodium tablets) | 7,718,634; 7,410,957; 6,294,196 |
| Glenmark Generics Ltd. v. GlaxoSmithKline, PLC, 13-0135 (D. Del.) | Jan. 24, 2013 | Hon. Christopher J. Burke | Bactroban® (mupirocin calcium cream) | 6,025,389; 5,569,672 |
| AbbVie, Inc. v. Sun Pharma. Indus. Ltd., 13-0138 (D. Del.) | Jan. 24, 2013 | Hon. Gregory M. Sleet | Zemplar® (paricalcitol capsules) | 5,597,815 |
| Pfizer Inc. v. Wockhardt Ltd., 13-0143 (D. Del.) | Jan. 25, 2013 | Hon. Gregory M. Sleet | Lyrica® (pregabalin oral solution) | 6,197,819 |
| Santarus, Inc. v. Mylan Inc., 13-0145 (D. Del.) | Jan. 28, 2013 | Hon. Richard G. Andrews | Fenoglide® (fenofibrate orally disintegrating tablets) | 7,658,944; 8,124,125 |
| Auxilium Pharma., Inc. v. Upsher-Smith Labs., Inc., 13-0148 (D. Del.) | Jan. 28, 2013 | Hon. Sue L. Robinson | Testim® (testosterone transdermal gel) | 7,320,968; 7,608,605; 7,608,606; 7,608,607; 7,608,608; 7,608,609; 7,608,610; 7,935,690; 8,063,029; 8,178,518 |
| Depomed, Inc. v. Purdue Pharma L.P., 13-0571 (D.N.J.) | Jan. 29, 2013 | Hon. Joel A. Pisano | OcyContin® (oxycodone hydrochloride controlled-release tablets) | 6,340,475; 6,635,280; 6,723,340 |
| Santarus, Inc. v. Mylan Pharma., Inc., 13-0017 (N.D.W.V.) | Jan. 30, 2013 | Hon. Irene M. Keeley | Fenoglide® (fenofibrate orally disintegrating tablets) | 7,658,944; 8,124,125 |
| Purdue Pharma L.P. v. Epic Pharma, LLC, 13-0683 (S.D.N.Y.) | Jan. 30, 2013 | Hon. Sidney H. Stein | OcyContin® (oxycodone hydrochloride extended-release tablets) | 7,674,799; 7,674,800; 7,683,072 |
| Purdue Pharma L.P. v. Impax Labs., Inc., 13-0684 (S.D.N.Y.) | Jan. 30, 2013 | Hon. Sidney H. Stein | OcyContin® (oxycodone hydrochloride extended-release tablets) | 7,674,799; 7,674,800; 7,683,072 |
| Merck Sharp & Dohme Corp. v. APP Pharma., Inc., 13-0166 (D. Del.) | Jan. 31, 2013 | Hon. Richard G. Andrews | Integrilin® (eptifibatide injection) | 5,807,825; 5,747,447; 5,968,902 |
| Purdue Pharma L.P. v. Watson Labs., Inc.—Florida, 13-0762 (S.D.N.Y.) | Feb. 1, 2013 | Hon. Sidney H. Stein | OcyContin® (oxycodone hydrochloride extended-release tablets) | 8,309,060 |
| Purdue Pharma L.P. v. Impax Labs., Inc., 13-0763 (S.D.N.Y.) | Feb. 1, 2013 | Hon. Sidney H. Stein | OcyContin® (oxycodone hydrochloride extended-release tablets) | 8,114,383; 8,309,060 |
| Cadence Pharma., Inc. v. Sandoz Inc., 13-0278 (S.D. Ca.) | Feb. 4, 2013 | Hon. John A. Houston | Ofirmev® (acetaminophen for injection) | 6,028,222; 6,992,218 |
| Cadence Pharma., Inc. v. Sandoz Inc., 13-0733 (D.N.J.) | Feb. 5, 2013 | Hon. Freda L. Wolfson | Ofirmev® (acetaminophen for injection) | 6,028,222; 6,992,218 |
| Sucampo AG v. Anchen Pharma., Inc., 13-0202 (D. Del.) | Feb. 7, 2013 | Hon. Gregory M. Sleet | Amitiza® (lubiprostone capsules) | 6,414,016; 7,795,312; 8,026,393; 8,071,613; 8,097,653; 8,338,639 |
| Unimed Pharma., LLC v. Perrigo Co., 13-0236 (D. Del.) | Feb. 15, 2013 | Hon. Leonard P. Stark | AndroGel® (testosterone gel) | 6,503,894 |
| Novartis Pharma. Corp. v. Actavis LLC, 13-1028 (D.N.J.) | Feb. 20, 2013 | Hon. Susan D. Wigenton | Zometa® (zoledronic acid for injection); Reclast® (zoledronic acid for injection) | 7,932,241; 8,052,987; 8,324,189 |
| Purdue Pharma L.P. v. Watson Labs., Inc.—Florida, 13-1272 (S.D.N.Y.) | Feb. 25, 2013 | Hon. Sidney H. Stein | OcyContin® (oxycodone hydrochloride extended-release tablets) | 8,337,888 |
| Depomed, Inc. v. Watson Labs., Inc.—Florida, 13-0342 (D. Del.) | Feb. 28, 2013 | Hon. Sue L. Robinson | Glumetza® (metformin hydrochloride extended-release tablets) | 6,488,962; 6,723,340; 6,635,280; 6,340,475 |
| Eli Lilly and Co. v. Accord Healthcare, Inc., USA, 13-0335 (S.D. Ind.) | Feb. 28, 2013 | Hon. William T. Lawrence | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
| Endo Pharma. Inc. v. Watson Pharma., Inc., 13-0192 (E.D. Tex.) | Feb. 28, 2013 | Hon. J. Rodney Gilstrap | Fortesta® (testosterone gel) | 6,319,913; 6,579,865 |
| AbbVie Inc. v. The Kennedy Trust for Rheumatology Research, 13-1358 (S.D.N.Y.) | Feb. 28, 2013 | Hon. Paul A. Crotty | Humira® (adalimumab) | 8,298,537; 8,383,120 |
| G.D. Searle LLC v. Lupin Pharma., Inc., 13-0121 (E.D. Va.) | Mar. 5, 2013 | Hon. Arenda L. Wright Allen | Celebrex® (celecoxib capsules) | RE44,048 |
| Novartis Pharma. Corp. v. Alvogen Pine Brook, Inc., 13-0370 (D. Del.) | Mar. 7, 2013 | Hon. Richard G. Andrews | Exelon® Patch (rivastigmine transdermal system or extended-release film) | 6,316,023; 6,335,031 |
| Novartis Pharma. Corp. v. Actavis, Inc., 13-0371 (D. Del.) | Mar. 7, 2013 | Hon. Richard G. Andrews | Exelon® Patch (rivastigmine transdermal system or extended-release film) | 6,316,023; 6,335,031 |
| Merck, Sharp & Dohme Corp. v. Hetero USA Inc., 13-1402 (D.N.J.) | Mar. 7, 2013 | Hon. Jerome B. Simandle | Sustiva® (efavirenz tablets) | 6,639,071; 6,939,964; 6,673,372 |
| Janssen Products, L.P. v. Hetero Drugs, Ltd., 13-1444 (D.N.J.) | Mar. 8, 2013 | Hon. William H. Walls | Prezista® (darunavir) | 7,126,015; 7,595,408 |
| Intendis Gmbh v. Glenmark Generics Ltd., 13-0421 (D. Del.) | Mar. 14, 2013 | Hon. Sue L. Robinson | Finacea® (azelaic acid gel) | 6,534,070 |
| Apotex, Inc. v. Teva Pharma. Indus., Ltd., 13-60601 (S.D. Fl.) | Mar. 14, 2013 | Hon. Donald M. Middlebrooks | Accupril® (quinapril hydrochloride) | 6,531,486 |
| Boehringer Ingelheim Pharma Gmbh & Co. KG v. Kremers Urban Pharma. Inc., 13-1580 (D.N.J.) | Mar. 14, 2013 | Hon. Noel L. Hillman | Aggrenox® (dipyridamole / aspirin extended-release capsules) | 6,015,577 |
| Pharmacia & Upjohn Co. LLC v. Apotex Inc., 13-2034 (N.D. Ill.) | Mar. 15, 2013 | Hon. Matthew F. Kennelly | Zyvox® (linezolid tablets) | 5,688,792 |
| AstraZeneca AB v. Watson Labs., Inc.—Florida, 13-1669 (D.N.J.) | Mar. 19, 2013 | Hon. Joel A. Pisano | Nexium® (esomeprazole magnesium delayed-release capsules) | 5,714,504; 5,877,192; 6,369,085; 6,875,872; 7,411,070 |
| Pfizer Inc. v. Lupin Ltd., 13-1778 (D.N.J.) | Mar. 21, 2013 | Hon. Dennis M. Cavanaugh | Detrol® LA (tolterodine tartrate extended-release capsules) | 6,630,162; 6,770,295 |
| Millenium Pharma., Inc. v. Fresenius KABI USA, LLC, 13-0467 (D. Del.) | Mar. 22, 2013 | Hon. Gregory M. Sleet | Velcade® (bortezomib) | 6,713,446; 6,958,319 |
| Takeda Pharma. U.S.A., Inc. v. Amneal Pharma., LLC, 13-0493 (D. Del.) | Mar. 28, 2013 | Hon. Sue L. Robinson | Colcrys® (colchicine) | 7,619,004; 7,601,758; 7,820,681; 7,915,269; 7,964,647; 7,964,648; 7,981,938; 8,093,296; 8,093,297; 8,097,655 |
| Mallinckrodt LLC v. Taro Pharma. Indus. Ltd., 13-0494 (D. Del.) | Mar. 28, 2013 | Hon. Richard G. Andrews | Pennsaid® (diclofenac sodium topical solution) | 8,217,078 |
| Unimed Pharma., LLC v. Watson Labs., Inc., 13-0496 (D. Del.) | Mar. 29, 2013 | Hon. Leonard P. Stark | AndroGel® (testosterone gel) | 6,503,894 |
GENERICally Speaking Spring 2013
Related Professionals
Related Publications
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
August 2, 2021
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.